CL2012001267A1 - Preparación oftálmica que comprende un factor neurotrófico derivado del cerebro (bdnf) en una concentración de al menos 15 µg/µl, útil para la prevención y/o tratamiento de enfermedades neurodegenerativas de la retina, nervio óptico y cuerpo genicular lateral. - Google Patents
Preparación oftálmica que comprende un factor neurotrófico derivado del cerebro (bdnf) en una concentración de al menos 15 µg/µl, útil para la prevención y/o tratamiento de enfermedades neurodegenerativas de la retina, nervio óptico y cuerpo genicular lateral.Info
- Publication number
- CL2012001267A1 CL2012001267A1 CL2012001267A CL2012001267A CL2012001267A1 CL 2012001267 A1 CL2012001267 A1 CL 2012001267A1 CL 2012001267 A CL2012001267 A CL 2012001267A CL 2012001267 A CL2012001267 A CL 2012001267A CL 2012001267 A1 CL2012001267 A1 CL 2012001267A1
- Authority
- CL
- Chile
- Prior art keywords
- genicular
- bdnf
- retina
- brain
- prevention
- Prior art date
Links
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 title abstract 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 210000001328 optic nerve Anatomy 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 210000001525 retina Anatomy 0.000 title abstract 2
- 101150035467 BDNF gene Proteins 0.000 title 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 1
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 1
- 240000004584 Tamarindus indica Species 0.000 abstract 1
- 235000004298 Tamarindus indica Nutrition 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000003889 eye drop Substances 0.000 abstract 1
- 229940012356 eye drops Drugs 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 239000003900 neurotrophic factor Substances 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERO A UNA PREPARACIÓN OFTÁLMICA EN FORMA DE GOTAS PARA OJOS QUE COMPRENDE UN FACTOR NEUROTRÓFICO DERIVADO DO> CEREBRO (BDNF) ERA UNA CONCENTRACIÓN DE AL MENOS 15 PG/IL, Y UNA SOLUCIÓN V(SCOSIFLCADA COMO PODADOR FARMACÉUTICAMONTE ACEPTABLE QUE COMPRENDE POLISACÁRIDO EXTRAÍDO DE SEMILLAS DE TAMARINDO (TSP) CON UNA CONCENTRACIÓN QUE VARIA DESDE 0,05 HASTA 2 <em>PLV, </em>LA CUAL ES ÚTIL PARA LN PREVENCIÓN Y/O TRALAMIENTO DO ENFERMEDADES NEURODEGENERATIVAS DE LA RETINA, NERVIO ÓPTICO Y CUERPO GENICULAR LATERA).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2009A002012A IT1396607B1 (it) | 2009-11-16 | 2009-11-16 | Preparazioni oftalmiche a base di bdnf (brain-derived neurotrophic factor) e loro uso. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012001267A1 true CL2012001267A1 (es) | 2012-12-07 |
Family
ID=42211955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012001267A CL2012001267A1 (es) | 2009-11-16 | 2012-05-15 | Preparación oftálmica que comprende un factor neurotrófico derivado del cerebro (bdnf) en una concentración de al menos 15 µg/µl, útil para la prevención y/o tratamiento de enfermedades neurodegenerativas de la retina, nervio óptico y cuerpo genicular lateral. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9387164B2 (es) |
| EP (1) | EP2501362B1 (es) |
| JP (2) | JP2013510844A (es) |
| KR (1) | KR101831793B1 (es) |
| CN (2) | CN105769750A (es) |
| BR (1) | BR112012011542A2 (es) |
| CA (1) | CA2781008C (es) |
| CL (1) | CL2012001267A1 (es) |
| CY (1) | CY1115853T1 (es) |
| DK (1) | DK2501362T3 (es) |
| ES (1) | ES2524976T3 (es) |
| HR (1) | HRP20141129T1 (es) |
| IT (1) | IT1396607B1 (es) |
| MX (1) | MX341502B (es) |
| PL (1) | PL2501362T3 (es) |
| PT (1) | PT2501362E (es) |
| RS (1) | RS53687B1 (es) |
| RU (1) | RU2564920C2 (es) |
| SI (1) | SI2501362T1 (es) |
| WO (1) | WO2011058449A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913468YA (en) * | 2015-07-13 | 2020-03-30 | Tohoku Techno Arch Co Ltd | Composition for optic nerve protection |
| ITUA20162343A1 (it) * | 2016-04-06 | 2017-10-06 | Luciano Domenici | Formulazioni intranasali di bdnf per uso nel trattamento di malattie neurodegenerative |
| CN111317814B (zh) * | 2020-04-23 | 2020-12-18 | 中国中医科学院眼科医院 | 一种冰片联合神经营养因子组合物及应用 |
| EP4616865A1 (en) * | 2024-03-13 | 2025-09-17 | Dompe' Farmaceutici SpA | Bdnf for the treatment of rhodopsin-mediated retinitis pigmentosa |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1283911B1 (it) * | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| JPH10212241A (ja) | 1996-05-27 | 1998-08-11 | Sumitomo Pharmaceut Co Ltd | Ｂｄｎｆを安定に含有する製剤 |
| KR100514277B1 (ko) * | 1996-09-13 | 2005-09-13 | 유겐가이샤 사이센딴이가꾸겡꾸쇼 | 신경 영양 인자의 안과용 조성물, 시신경 기능 장애 치료제 및 시신경 기능 장애 치료 방법 |
| IT1305294B1 (it) | 1999-01-29 | 2001-05-04 | Alessandro Lambiase | Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari. |
| JP2003048851A (ja) * | 2001-08-03 | 2003-02-21 | Nidek Co Ltd | 視細胞障害疾患治療薬 |
| WO2006046584A1 (ja) | 2004-10-26 | 2006-05-04 | Santen Pharmaceutical Co., Ltd. | 視細胞障害治療剤 |
| US20070014760A1 (en) * | 2005-07-18 | 2007-01-18 | Peyman Gholam A | Enhanced recovery following ocular surgery |
| WO2007101204A1 (en) * | 2006-02-27 | 2007-09-07 | Alcon Research, Ltd. | Method of treating glaucoma |
| ITRM20070510A1 (it) * | 2007-10-02 | 2009-04-03 | Rmfa Trading S A | Composizioni oftalmiche a base di polisaccaride del seme di tamarindo e acido ialuronico. |
-
2009
- 2009-11-16 IT ITMI2009A002012A patent/IT1396607B1/it active
-
2010
- 2010-11-12 HR HRP20141129AT patent/HRP20141129T1/hr unknown
- 2010-11-12 MX MX2012005624A patent/MX341502B/es active IP Right Grant
- 2010-11-12 WO PCT/IB2010/003220 patent/WO2011058449A2/en not_active Ceased
- 2010-11-12 CA CA2781008A patent/CA2781008C/en not_active Expired - Fee Related
- 2010-11-12 EP EP10809037.4A patent/EP2501362B1/en active Active
- 2010-11-12 BR BR112012011542A patent/BR112012011542A2/pt not_active IP Right Cessation
- 2010-11-12 JP JP2012538434A patent/JP2013510844A/ja active Pending
- 2010-11-12 SI SI201030793T patent/SI2501362T1/sl unknown
- 2010-11-12 ES ES10809037.4T patent/ES2524976T3/es active Active
- 2010-11-12 PL PL10809037T patent/PL2501362T3/pl unknown
- 2010-11-12 US US13/509,824 patent/US9387164B2/en not_active Expired - Fee Related
- 2010-11-12 PT PT108090374T patent/PT2501362E/pt unknown
- 2010-11-12 RU RU2012120096/15A patent/RU2564920C2/ru not_active IP Right Cessation
- 2010-11-12 CN CN201610053193.6A patent/CN105769750A/zh active Pending
- 2010-11-12 KR KR1020127012512A patent/KR101831793B1/ko not_active Expired - Fee Related
- 2010-11-12 DK DK10809037.4T patent/DK2501362T3/en active
- 2010-11-12 CN CN2010800516551A patent/CN102639111A/zh active Pending
- 2010-11-12 RS RS20140644A patent/RS53687B1/sr unknown
-
2012
- 2012-05-15 CL CL2012001267A patent/CL2012001267A1/es unknown
-
2014
- 2014-12-02 CY CY20141101003T patent/CY1115853T1/el unknown
-
2015
- 2015-11-09 JP JP2015219649A patent/JP2016026229A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2781008C (en) | 2018-02-06 |
| PT2501362E (pt) | 2014-12-04 |
| DK2501362T3 (en) | 2014-11-17 |
| CA2781008A1 (en) | 2011-05-19 |
| CN102639111A (zh) | 2012-08-15 |
| US9387164B2 (en) | 2016-07-12 |
| EP2501362A2 (en) | 2012-09-26 |
| CN105769750A (zh) | 2016-07-20 |
| KR101831793B1 (ko) | 2018-02-23 |
| US20120258916A1 (en) | 2012-10-11 |
| WO2011058449A3 (en) | 2011-12-01 |
| SI2501362T1 (sl) | 2014-12-31 |
| ITMI20092012A1 (it) | 2011-05-17 |
| MX2012005624A (es) | 2012-09-28 |
| WO2011058449A2 (en) | 2011-05-19 |
| RU2564920C2 (ru) | 2015-10-10 |
| ES2524976T3 (es) | 2014-12-16 |
| PL2501362T3 (pl) | 2015-02-27 |
| HRP20141129T1 (hr) | 2015-01-02 |
| KR20120101390A (ko) | 2012-09-13 |
| CY1115853T1 (el) | 2017-01-25 |
| EP2501362B1 (en) | 2014-10-08 |
| JP2016026229A (ja) | 2016-02-12 |
| RU2012120096A (ru) | 2013-11-20 |
| RS53687B1 (sr) | 2015-04-30 |
| JP2013510844A (ja) | 2013-03-28 |
| MX341502B (es) | 2016-08-22 |
| IT1396607B1 (it) | 2012-12-14 |
| BR112012011542A2 (pt) | 2016-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013166449A3 (en) | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | |
| BR112017024531A2 (pt) | lentes intraoculares ajustáveis por luz usando nanopartículas de conversão ascendente e luz do infravermelho próximo (nir) | |
| EA201101575A1 (ru) | Лечение наследственной оптической (зрительной) нейропатии лебера и доминантной атрофии зрительного нерва токотриенол хинонами | |
| BR112016000546A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| EP4424326A3 (en) | Modified nk-92 cells for treating cancer | |
| PH12018500401B1 (en) | Antibodies specific for tgf-beta | |
| MX362185B (es) | Composiciones y tratamiento para enfermedades y trastornos del ojo. | |
| BR112015004465A2 (pt) | sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem | |
| BR112016013109A2 (pt) | anticorpos de anti-siglec-8 e métodos de seu uso | |
| BR112013017745A2 (pt) | métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho | |
| MX394103B (es) | Anticuerpos anti-angptl8 y usos de estos. | |
| PE20151771A1 (es) | Composiciones nutricionales que contienen un componente neurologico y los usos del mismo | |
| AR099019A1 (es) | Módulos lanzadera monovalentes de la barrera hematocefálica | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| WO2015130821A3 (en) | Illuminated treatment probe for delivering laser energy | |
| GT201200258A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| IN2012DN02645A (es) | ||
| MX2011013060A (es) | Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas. | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| GB2513675A (en) | Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow | |
| PH12013501671A1 (en) | Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate | |
| BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
| CL2012001267A1 (es) | Preparación oftálmica que comprende un factor neurotrófico derivado del cerebro (bdnf) en una concentración de al menos 15 µg/µl, útil para la prevención y/o tratamiento de enfermedades neurodegenerativas de la retina, nervio óptico y cuerpo genicular lateral. | |
| EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
| CR20140473A (es) | Compuestos de pirazol como inhibidores de sglt1 |